Frederic Jacques de Bure

Director/Board Member at Inpellis, Inc.

52 year

Consumer Services

Health Technology

Profile

Frederic Jacques de Bure is an Independent Director at Inpellis, Inc. and a General Partner at Nusantara Ventures Singapore Pte Ltd.
He was previously a Non-Affiliated Director at PT Visi Media Asia Tbk.
Mr. de Bure holds an MBA from The University of Chicago and an undergraduate degree from Vassar College.

Frederic Jacques de Bure active positions

Companies	Position	Start
Nusantara Ventures Singapore Pte Ltd.	Corporate Officer/Principal	31/12/2008
Inpellis, Inc. Inpellis, Inc. Pharmaceuticals: MajorHealth Technology Inpellis, Inc. operates as a specialty pharmaceutical company that focuses on developing and commercializing transdermal prescription therapeutics for treating acute and chronic pain resulting from musculoskeletal disorders and peripheral neuropathy. Its products include transdermal ibuprofen for moderate to severe osteoarthritis and transdermal benfotiamine for painful diabetic neuropathy. The company was founded in 2012 and is headquartered in Haddonfield, NJ.	Director/Board Member	31/12/2014

All active positions of Frederic Jacques de Bure

Former positions of Frederic Jacques de Bure

Companies	Position	End
PT VISI MEDIA ASIA TBK	Corporate Officer/Principal	19/03/2012

See the detail of Frederic Jacques de Bure's experience

Training of Frederic Jacques de Bure

The University of Chicago	Masters Business Admin
Vassar College	Undergraduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Frederic Jacques de Bure's experience

Connections

100 +

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
PT VISI MEDIA ASIA TBK	Consumer Services

Private companies	2
Nusantara Ventures Singapore Pte Ltd.
Inpellis, Inc. Inpellis, Inc. Pharmaceuticals: MajorHealth Technology Inpellis, Inc. operates as a specialty pharmaceutical company that focuses on developing and commercializing transdermal prescription therapeutics for treating acute and chronic pain resulting from musculoskeletal disorders and peripheral neuropathy. Its products include transdermal ibuprofen for moderate to severe osteoarthritis and transdermal benfotiamine for painful diabetic neuropathy. The company was founded in 2012 and is headquartered in Haddonfield, NJ.	Health Technology